IN2014MN01875A - - Google Patents
Info
- Publication number
- IN2014MN01875A IN2014MN01875A IN1875MUN2014A IN2014MN01875A IN 2014MN01875 A IN2014MN01875 A IN 2014MN01875A IN 1875MUN2014 A IN1875MUN2014 A IN 1875MUN2014A IN 2014MN01875 A IN2014MN01875 A IN 2014MN01875A
- Authority
- IN
- India
- Prior art keywords
- compounds
- parp1
- present
- parp
- wnt signalling
- Prior art date
Links
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 abstract 6
- 101000663006 Homo sapiens Poly [ADP-ribose] polymerase tankyrase-1 Proteins 0.000 abstract 3
- 101000662592 Homo sapiens Poly [ADP-ribose] polymerase tankyrase-2 Proteins 0.000 abstract 3
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 abstract 3
- 102100037664 Poly [ADP-ribose] polymerase tankyrase-1 Human genes 0.000 abstract 3
- 102100037477 Poly [ADP-ribose] polymerase tankyrase-2 Human genes 0.000 abstract 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000011664 signaling Effects 0.000 abstract 3
- 230000001668 ameliorated effect Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical class C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607680P | 2012-03-07 | 2012-03-07 | |
| PCT/GB2013/050561 WO2013132253A1 (en) | 2012-03-07 | 2013-03-07 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01875A true IN2014MN01875A (es) | 2015-07-03 |
Family
ID=47891779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1875MUN2014 IN2014MN01875A (es) | 2012-03-07 | 2013-03-07 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9193689B2 (es) |
| EP (1) | EP2822656B1 (es) |
| JP (1) | JP6082409B2 (es) |
| KR (1) | KR102104144B1 (es) |
| CN (1) | CN104302358B (es) |
| AU (1) | AU2013229229B2 (es) |
| CA (1) | CA2865511A1 (es) |
| DK (1) | DK2822656T3 (es) |
| ES (1) | ES2611504T3 (es) |
| IN (1) | IN2014MN01875A (es) |
| MX (1) | MX346147B (es) |
| RU (1) | RU2696572C2 (es) |
| WO (1) | WO2013132253A1 (es) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11972017B2 (en) | 2020-10-21 | 2024-04-30 | Verint Americas Inc. | System and method of automated determination of use of sensitive information and corrective action for improper use |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2822656T3 (en) | 2012-03-07 | 2017-01-30 | Inst Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| RS59921B1 (sr) | 2012-08-08 | 2020-03-31 | Merck Patent Gmbh | (aza-)izohinolinon derivati |
| EP3044221B1 (en) | 2013-09-11 | 2018-02-21 | Institute of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| EP3356345B1 (en) * | 2015-09-30 | 2023-11-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Heteroaryl derivatives as sepiapterin reductase inhibitors |
| CN108289448B (zh) | 2015-12-02 | 2021-10-22 | 先正达参股股份有限公司 | 杀微生物的噁二唑衍生物 |
| UY37623A (es) | 2017-03-03 | 2018-09-28 | Syngenta Participations Ag | Derivados de oxadiazol tiofeno fungicidas |
| WO2018219773A1 (en) | 2017-06-02 | 2018-12-06 | Syngenta Participations Ag | Fungicidal compositions |
| WO2018219825A1 (en) | 2017-06-02 | 2018-12-06 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
| CA3067309A1 (en) | 2017-06-28 | 2019-01-03 | Syngenta Participations Ag | Fungicidal compositions |
| WO2019011929A1 (en) | 2017-07-11 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
| WO2019011926A1 (en) | 2017-07-11 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
| WO2019011923A1 (en) | 2017-07-11 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
| WO2019011928A1 (en) | 2017-07-11 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
| BR112020000371A2 (pt) | 2017-07-12 | 2020-07-14 | Syngenta Participations Ag | derivados de oxadiazol microbiocidas |
| WO2019012003A1 (en) | 2017-07-13 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
| EP3459469A1 (en) | 2017-09-23 | 2019-03-27 | Universität Zürich | Medical occluder device |
| AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
| US20210267204A1 (en) | 2018-07-16 | 2021-09-02 | Syngenta Crop Protection Ag | Microbiocidal oxadiazole derivatives |
| HRP20231413T1 (hr) | 2019-04-12 | 2024-02-16 | Riboscience Llc | Derivati bicikličnih heteroarila kao inhibitori ektonukleotid pirofosfataze fosfodiesteraze 1 |
| AR118673A1 (es) | 2019-04-18 | 2021-10-20 | Syngenta Crop Protection Ag | Procedimiento para la preparación de derivados de oxadiazol microbiocidas |
| JP7531236B2 (ja) | 2019-09-26 | 2024-08-09 | ウニベルシタット チューリッヒ | 左心耳閉鎖デバイス |
| AU2020376697B2 (en) * | 2019-10-30 | 2024-03-14 | Digmbio. Inc. | Isoquinolinone derivative, preparation method therefor, and pharmaceutical composition, comprising same as active ingredient, for prevention or treatment of poly(ADP-ribose)polymerase-1 (PARP-1)-associated disease |
| WO2022194799A1 (de) | 2021-03-18 | 2022-09-22 | Merck Patent Gmbh | Heteroaromatische verbindungen für organische elektrolumineszenzvorrichtungen |
| EP4334278A1 (en) * | 2021-05-04 | 2024-03-13 | Board of Regents, The University of Texas System | Indanone and tetralone-keto or hydroxyl oximes as cancer therapeutics |
| CN115572262B (zh) * | 2022-10-27 | 2024-08-27 | 厦门沃克沃德医药科技有限公司 | 一种异喹啉衍生物及其制备方法 |
| WO2024238871A1 (en) * | 2023-05-18 | 2024-11-21 | Rectify Pharmaceuticals, Inc. | Aryl sulfonamide compounds and their use in treating medical conditions |
| GB2634228A (en) * | 2023-10-02 | 2025-04-09 | Duke Street Bio Ltd | PARP1 inhibitor compounds |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2851458A (en) | 1955-06-08 | 1958-09-09 | Burroughs Wellcome Co | Diquaternary compounds and the manufacture thereof |
| US3464563A (en) | 1967-02-06 | 1969-09-02 | American Air Filter Co | Liquid filter apparatus |
| US4678500A (en) | 1984-06-29 | 1987-07-07 | E. I. Du Pont De Nemours And Company | Herbicidal 2,6-disubstituted benzylsulfonamides and benzenesulfamates |
| US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| US4942163A (en) | 1989-03-07 | 1990-07-17 | E. I. Du Pont De Nemours And Company | 1(2H)-isoquinolinones and 1-isoquinolineamines as cancer chemotherapeutic agents |
| DE69839887D1 (de) | 1997-10-02 | 2008-09-25 | Eisai R&D Man Co Ltd | Kondensierte pyridinderivate |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| EP1396488A1 (en) | 2001-05-23 | 2004-03-10 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
| HRP20080382A2 (en) | 2001-09-21 | 2008-12-31 | Bristol-Myers Squibb Company A Delaware (Usa) Corporation | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| JPWO2004009556A1 (ja) | 2002-07-24 | 2005-11-17 | 杏林製薬株式会社 | ４−置換アリール−５−ヒドロキシイソキノリノン誘導体 |
| KR100735781B1 (ko) | 2002-10-01 | 2007-07-06 | 미쯔비시 웰 파마 가부시키가이샤 | 이소퀴놀린 화합물 및 그의 의약 용도 |
| JP2006506379A (ja) | 2002-10-23 | 2006-02-23 | グレンマーク・ファーマシューティカルズ・リミテッド | 炎症性およびアレルギー性疾患の治療に有用な新規三環式化合物：その調製方法およびそれらを含む医薬組成物 |
| WO2004058717A1 (en) | 2002-12-20 | 2004-07-15 | X-Ceptor Therapeutics, Inc. | Isoquinolinone derivatives and their use as therapeutic agents |
| EP1629000B1 (en) | 2003-04-16 | 2009-02-18 | Bristol-Myers Squibb Company | Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus |
| TW200536830A (en) | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
| WO2005075432A1 (ja) | 2004-02-06 | 2005-08-18 | Chugai Seiyaku Kabushiki Kaisha | １−（２ｈ）−イソキノロン誘導体およびその抗ガン剤としての使用 |
| WO2005113540A1 (ja) | 2004-05-20 | 2005-12-01 | Mitsubishi Pharma Corporation | イソキノリン化合物及びその医薬用途 |
| WO2006045010A2 (en) | 2004-10-20 | 2006-04-27 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| CA2585053C (en) | 2004-10-22 | 2011-07-12 | Janssen Pharmaceutica N.V. | Substituted n-acyl (hetero)aryl compounds as c-fms kinase inhibitors |
| CN101080392B (zh) | 2004-12-16 | 2010-05-05 | 霍夫曼-拉罗奇有限公司 | 作为抗肥胖药剂的哌嗪基吡啶衍生物 |
| TWI389897B (zh) | 2005-02-22 | 2013-03-21 | Chugai Pharmaceutical Co Ltd | 1- (2H) -isoquinolinone derivatives |
| TW200722420A (en) | 2005-03-31 | 2007-06-16 | Astellas Pharma Inc | Propane-1,3-dion derivative or salt thereof |
| WO2007016525A2 (en) | 2005-07-29 | 2007-02-08 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| KR20080039508A (ko) * | 2005-08-24 | 2008-05-07 | 이노텍 파마슈티컬스 코포레이션 | 인데노이소퀴놀리논 유사체 및 이의 사용 방법 |
| AU2007292155B2 (en) | 2006-09-05 | 2012-11-01 | Kyowa Kirin Co., Ltd. | Imidazole derivative |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2007345526B2 (en) | 2007-02-01 | 2013-02-28 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular diseases |
| FR2919286A1 (fr) * | 2007-07-27 | 2009-01-30 | Sanofi Aventis Sa | Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique. |
| US20090054392A1 (en) | 2007-08-20 | 2009-02-26 | Wyeth | Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| WO2009027650A1 (en) | 2007-08-24 | 2009-03-05 | The Institute Of Cancer: Royal Cancer Hospital | Materials and methods for exploiting synthetic lethality in brca-associated cancers |
| CA2704648A1 (en) | 2007-11-05 | 2009-05-14 | Novartis Ag | Methods and compositions for measuring wnt activation and for treating wnt-related cancers |
| DE102008019838A1 (de) | 2008-04-19 | 2009-12-10 | Boehringer Ingelheim International Gmbh | Neue Arylsulfonylglycin-Derivate, deren Herstellung und deren Verwendung als Arzneimittel |
| WO2009132000A1 (en) | 2008-04-22 | 2009-10-29 | Janssen Pharmaceutica Nv | Quinoline or isoquinoline substituted p2x7 antagonists |
| EP2362775B1 (en) | 2008-11-20 | 2015-08-05 | GlaxoSmithKline LLC | Chemical compounds |
| SG174252A1 (en) | 2009-03-06 | 2011-10-28 | Hoffmann La Roche | Heterocyclic antiviral compounds |
| AU2010224523B2 (en) | 2009-03-18 | 2014-05-08 | Resverlogix Corp. | Novel anti-inflammatory agents |
| MX374414B (es) | 2009-04-22 | 2025-03-06 | Resverlogix Corp | Nuevos agentes anti-inflamatorios. |
| TWI499418B (zh) | 2009-05-21 | 2015-09-11 | Nerviano Medical Sciences Srl | 異喹啉－１（２ｈ）－酮衍生物 |
| BR112012008518A2 (pt) | 2009-10-13 | 2016-04-05 | Msd Oss Bv | derivado heterocíclico, e, composição farmacêutica |
| JP5951600B2 (ja) | 2010-05-21 | 2016-07-13 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | キナーゼ調節のための、化合物、組成物および方法 |
| EP2582680A1 (en) | 2010-06-17 | 2013-04-24 | Novartis AG | Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
| CN103814032A (zh) | 2011-07-13 | 2014-05-21 | 诺华股份有限公司 | 用作端锚聚合酶抑制剂的4-氧代-3,5,7,8-四氢-4H-吡喃并[4,3-d]嘧啶基化合物 |
| JP2014520858A (ja) | 2011-07-13 | 2014-08-25 | ノバルティス アーゲー | タンキラーゼ阻害剤として用いるための新規な２−ピペリジン−１−イル−アセトアミド化合物 |
| AU2012282076A1 (en) | 2011-07-13 | 2014-02-27 | Novartis Ag | 4 - piperidinyl compounds for use as tankyrase inhibitors |
| AU2012342562B2 (en) | 2011-11-25 | 2017-02-23 | Nerviano Medical Sciences S.R.L. | 3-phenyl-isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors |
| NZ624063A (en) | 2011-12-31 | 2016-09-30 | Beigene Ltd | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors |
| CA2860340C (en) | 2011-12-31 | 2017-04-25 | Beigene, Ltd. | Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors |
| AU2013212175B2 (en) | 2012-01-28 | 2017-03-02 | Cancer Research Technology Limited | Azaheterocyclic compounds |
| US9174980B2 (en) | 2012-01-31 | 2015-11-03 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds as inhibitors of leukotriene production |
| PE20141823A1 (es) | 2012-02-09 | 2014-11-29 | Merck Patent Gmbh | Derivados de tetrahidro-quinazolinona |
| EP2822944A1 (en) | 2012-03-05 | 2015-01-14 | Amgen, Inc. | Oxazolidinone compounds and derivatives thereof |
| DK2822656T3 (en) | 2012-03-07 | 2017-01-30 | Inst Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| KR102070567B1 (ko) | 2012-03-28 | 2020-01-29 | 메르크 파텐트 게엠베하 | 바이시클릭 피라지논 유도체 |
| US20130281397A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| HRP20161033T1 (hr) | 2012-05-04 | 2016-10-21 | Merck Patent Gmbh | Derivati pirolotriazinona |
| WO2013177349A2 (en) | 2012-05-25 | 2013-11-28 | Glaxosmithkline Llc | Quinazolinediones as tankyrase inhibitors |
| CN104540830A (zh) | 2012-06-07 | 2015-04-22 | 霍夫曼-拉罗奇有限公司 | 端锚聚合酶的吡唑并嘧啶酮和吡唑并吡啶酮抑制剂 |
| EP2858995A1 (en) | 2012-06-07 | 2015-04-15 | F. Hoffmann-La Roche AG | Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase |
| CA2869239A1 (en) | 2012-06-20 | 2013-12-27 | F. Hoffmann-La Roche Ag | Pyranopyridone inhibitors of tankyrase |
| WO2013189905A1 (en) | 2012-06-20 | 2013-12-27 | F. Hoffmann-La Roche Ag | Pyrrolopyrazone inhibitors of tankyrase |
| RS59921B1 (sr) | 2012-08-08 | 2020-03-31 | Merck Patent Gmbh | (aza-)izohinolinon derivati |
| US9505749B2 (en) | 2012-08-29 | 2016-11-29 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
| WO2014045101A1 (en) | 2012-09-21 | 2014-03-27 | Cellzome Gmbh | Tetrazolo quinoxaline derivatives as tankyrase inhibitors |
| AR092211A1 (es) | 2012-09-24 | 2015-04-08 | Merck Patent Ges Mit Beschränkter Haftung | Derivados de hidropirrolopirrol |
| WO2014048532A1 (en) | 2012-09-26 | 2014-04-03 | Merck Patent Gmbh | Quinazolinone derivatives as parp inhibitors |
| WO2014087165A1 (en) | 2012-12-06 | 2014-06-12 | University Of Bath | Tankyrase inhibitors |
-
2013
- 2013-03-07 DK DK13709994.1T patent/DK2822656T3/en active
- 2013-03-07 CN CN201380023162.0A patent/CN104302358B/zh not_active Expired - Fee Related
- 2013-03-07 KR KR1020147026143A patent/KR102104144B1/ko not_active Expired - Fee Related
- 2013-03-07 RU RU2014138194A patent/RU2696572C2/ru not_active Application Discontinuation
- 2013-03-07 US US14/381,712 patent/US9193689B2/en not_active Expired - Fee Related
- 2013-03-07 JP JP2014560442A patent/JP6082409B2/ja not_active Expired - Fee Related
- 2013-03-07 ES ES13709994.1T patent/ES2611504T3/es active Active
- 2013-03-07 CA CA2865511A patent/CA2865511A1/en not_active Abandoned
- 2013-03-07 IN IN1875MUN2014 patent/IN2014MN01875A/en unknown
- 2013-03-07 EP EP13709994.1A patent/EP2822656B1/en active Active
- 2013-03-07 MX MX2014010509A patent/MX346147B/es active IP Right Grant
- 2013-03-07 AU AU2013229229A patent/AU2013229229B2/en not_active Ceased
- 2013-03-07 WO PCT/GB2013/050561 patent/WO2013132253A1/en active Application Filing
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11972017B2 (en) | 2020-10-21 | 2024-04-30 | Verint Americas Inc. | System and method of automated determination of use of sensitive information and corrective action for improper use |
| US12265648B2 (en) | 2020-10-21 | 2025-04-01 | Verint Americas, Inc | System and method of automated determination of use of sensitive information and corrective action for improper use |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150001734A (ko) | 2015-01-06 |
| CN104302358B (zh) | 2017-12-05 |
| EP2822656B1 (en) | 2016-10-19 |
| JP6082409B2 (ja) | 2017-02-15 |
| US9193689B2 (en) | 2015-11-24 |
| MX2014010509A (es) | 2014-10-14 |
| WO2013132253A1 (en) | 2013-09-12 |
| US20150099732A1 (en) | 2015-04-09 |
| MX346147B (es) | 2017-03-09 |
| JP2015512885A (ja) | 2015-04-30 |
| RU2014138194A (ru) | 2016-04-27 |
| ES2611504T3 (es) | 2017-05-09 |
| AU2013229229B2 (en) | 2017-10-19 |
| AU2013229229A1 (en) | 2014-09-25 |
| DK2822656T3 (en) | 2017-01-30 |
| CA2865511A1 (en) | 2013-09-12 |
| RU2696572C2 (ru) | 2019-08-05 |
| KR102104144B1 (ko) | 2020-04-23 |
| CN104302358A (zh) | 2015-01-21 |
| EP2822656A1 (en) | 2015-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01875A (es) | ||
| MD20140109A2 (ro) | Compuşi ai indolului şi indazolului care activează AMPK | |
| PH12014502772A1 (en) | Substituted tricyclic compounds as fgfr inhibitors | |
| MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| MX356205B (es) | Benzopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr). | |
| NZ700928A (en) | Dna-pk inhibitors | |
| NZ707778A (en) | Therapeutic compounds and compositions and their use as pkm2 modulators | |
| IN2015DN01156A (es) | ||
| PH12015500825B1 (en) | Substituted benzene compounds | |
| NZ708382A (en) | Cycloalkyl bis-thiadiazole inhibitors of glutaminase and their use as therapeutic agents | |
| TN2016000238A1 (en) | Tricyclic compounds as anticancer agents. | |
| PH12014500867A1 (en) | Anticancer pyridopyrazines via the inhibition of fgfr kinases | |
| WO2014028591A3 (en) | N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| TN2014000016A1 (en) | 4 - piperidinyl compounds for use as tankyrase inhibitors | |
| MX362939B (es) | Derivados de (aza-)isoquinolinona. | |
| MX351149B (es) | Derivados biciclicos de pirazinona. | |
| MX362855B (es) | Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp). | |
| PH12014501581A1 (en) | Tetrahydro-quinazolinone derivatives as tank and parp inhibitors | |
| MX2016008042A (es) | Derivados de imidazopirazinona. | |
| IN2014CN04671A (es) | ||
| IN2015DN01223A (es) | ||
| PH12016502133A1 (en) | Substituted tricycle compounds as fgfr inhibitors |